The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susc
The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.
대표청구항▼
1. A method of detecting an autoimmune disease state or autoimmune disease susceptibility in a mammalian subject, comprising detecting an antibody in a bodily fluid test sample from the subject, wherein the antibody is characteristic of or associated with an autoimmune disease and wherein it is not
1. A method of detecting an autoimmune disease state or autoimmune disease susceptibility in a mammalian subject, comprising detecting an antibody in a bodily fluid test sample from the subject, wherein the antibody is characteristic of or associated with an autoimmune disease and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen,(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen for each amount of antigen used in step (a), and(d) comparing the curve of the test sample with a control sample curve,wherein a difference in the test sample curve when compared with the control sample curve indicates the presence of autoimmune disease state or autoimmune disease susceptibility the subject. 2. The method of claim 1, wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematous (SLE), primary biliary cirrhosis (PBC), autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune gastritis, pernicious anemia, autoimmune adrenalitis, Addison's disease, autoimmune hypoparathyroidism, autoimmune diabetes or myasthenia gravis. 3. A method of detecting kidney or hepatic disease leading to insufficiency or failure of either organ in a mammalian subject, comprising detecting an antibody in a bodily fluid test sample from the subject, wherein the antibody is characteristic of or associated with kidney or hepatic disease leading to insufficiency or failure of either organ and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen,(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen for each amount of antigen used in step (a), and(d) comparing the curve of the test sample with a control sample curve,wherein a difference in the test sample curve when compared with the control sample curve indicates kidney or hepatic disease leading to insufficiency or failure of either organ in the subject. 4. A method of detecting rejection of a tissue transplant in a mammalian subject, comprising detecting an antibody in a bodily fluid test sample from the subject, wherein the antibody is directed towards an epitope present on tissue transplanted into the mammalian subject and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen,(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen for each amount of antigen used in step (a), and(d) comparing the curve of the test sample with a control sample curve,wherein a difference in the test sample curve when compared with the control sample curve indicates tissue transplant rejection in the subject. 5. A method of detecting an antibody in a bodily fluid test sample from a mammalian subject, wherein the antibody is directed to a foreign substance introduced into the mammalian subject and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen, and(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen for each amount of antigen used in step (a), and(d) comparing the curve of the test sample with a control sample curve,wherein a difference in the test sample curve when compared with the control sample curve indicates the presence of the foreign substance in the subject. 6. The method of claim 5, further comprising detecting the presence of the antibody based upon the amount of specific binding between the antibody and the antigen at the different antigen concentrations used. 7. The method of claim 5, wherein detecting the presence of the antibody is based upon the collective values of the amount of specific binding for all the antigen concentrations tested. 8. The method of claim 5, wherein the presence in the test sample of antibody reactive with the antigen used in the assay is indicated by a generally S-shaped or sigmoidal curve. 9. The method of claim 5, wherein the mammalian subject is a human. 10. The method of claim 5, wherein the foreign substance is a therapeutic agent. 11. The method of claim 10, wherein the therapeutic agent is a drug, pro drug, or antibody therapy. 12. The method of claim 5, wherein the foreign substance is a vaccine. 13. The method of claim 11, wherein the foreign substance is a non-target portion of a therapeutic agent or vaccine. 14. The method of claim 13, wherein the non-target portion is biotin. 15. The method of claim 5, wherein the foreign substance is an infectious agent such as fungus, bacteria, virus or parasite. 16. A method of detecting an antibody in a bodily fluid test sample from a mammalian subject wherein the antibody is an autoantibody characteristic of or associated with an autoimmune disease and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen and(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen used in step (a) and(d) comparing the curve to a control curve,wherein a difference between the test sample curve and the control curve indicates the presence of antibody in the test sample. 17. A method of detecting an antibody in a bodily fluid test sample from a mammalian subject wherein the antibody is an autoantibody characteristic of or associated with a disease leading to insufficiency or failure of an organ and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen and(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen used in step (a) and(d) comparing the curve to a control curve,wherein a difference between the test sample curve and the control curve indicates the presence of antibody in the test sample. 18. The method of claim 17, wherein the disease is kidney or hepatic disease. 19. A method of detecting an antibody in a bodily fluid test sample from a mammalian subject wherein the antibody is directed towards an epitope present on tissue transplanted into the mammalian subject and wherein it is not known whether the test sample comprises the antibody, the method comprising: (a) contacting the test sample with a plurality of different amounts of an antigen specific for the antibody,(b) detecting the amount of specific binding between the antibody and the antigen and(c) plotting or calculating a curve of the amount of specific binding versus the amount of antigen used in step (a) and(d) comparing the curve to a control curve,wherein a difference between the test sample curve and the control curve indicates the presence of antibody in the test sample. 20. The method of claim 16, wherein the antigen is a naturally occurring protein or polypeptide, a recombinant protein or polynucleotide, a synthetic protein or polypeptide, synthetic peptide, peptide mimetic, polysaccharide or nucleic acid. 21. The method of claim 17, wherein the antigen is a naturally occurring protein or polypeptide, a recombinant protein or polynucleotide, a synthetic protein or polypeptide, synthetic peptide, peptide mimetic, polysaccharide or nucleic acid. 22. The method of claim 18, wherein the antigen is a naturally occurring protein or polypeptide, a recombinant protein or polynucleotide, a synthetic protein or polypeptide, synthetic peptide, peptide mimetic, polysaccharide or nucleic acid. 23. The method of claim 19, wherein the antigen is a naturally occurring protein or polypeptide, a recombinant protein or polynucleotide, a synthetic protein or polypeptide, synthetic peptide, peptide mimetic, polysaccharide or nucleic acid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (28)
Hanash, Samir M.; Misek, David; Hinderer, Robert; Beer, David; Brichory, Franck, Annexin proteins and autoantibodies as serum markers for cancer.
Webb Thomas E. (Columbus OH) Hanausek-Walaszek Margaret (Smithville TX) Mercurio Frank (La Jolla CA), Detection of circulating antibodies to a cancer marker protein.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Pardoll Drew M. ; Jaffee Elizabeth ; Adler Adam ; Topalian Suzanne L. ; Rosenberg Steven A., Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same.
Marks Jeffrey Robert (Hillsborough NC) Inglehart James Dirk (Durham NC) Davidoff Andrew Mark (Durham NC) Henslee Jerry G. (Libertyville IL), Method of detecting tumors containing complexes of p53 and HSP70.
Griffiths Andrew David,GBX ; Hoogenboom Hendricus Renerus Jacobus Mattheus,GBX ; Marks James David ; McCafferty John,GBX ; Winter Gregory Paul,GBX ; Grigg Geoffrey Walter,AUX, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.